Pipeline

At Vaxx Research, our proprietary CureiTec™ AI/ML platform powers the development of advanced therapies for cancer, autoimmune diseases, infectious diseases, and longevity. By integrating AI, gene editing, cell engineering, and non-viral delivery technologies, the CureiTec™ platform accelerates drug discovery and creates innovative solutions for unmet medical needs.

 

Key Technologies.

​

• ARVAC™: AI-assisted Replicon-based vaccines for precise and efficient immune activation for prophylactic and therapeutic applications.

• ARCS™: AI-assisted Nucleic acid-based & Adoptive Cell Therapy Systems designed for personalized, scalable, and curative treatments.

 

These technology platforms fuel our therapeutic pipeline and drive projects from early discovery to clinical readiness with unparalleled efficiency.

​

Enabled by CureiTec™, our pipeline spans multiple therapeutic areas:

 

• Cancer: Developing next-generation immunotherapies and personalized cancer vaccines.

• Autoimmune Diseases: Innovating treatments for improved immune modulation.

• Infectious Diseases: Advancing safe and effective cures and preventive solutions.

• Longevity: Exploring metabolic and genetic pathways to extend healthspan.

 

The chart below highlights the progress of these projects, from early discovery to clinical development. It demonstrates our commitment to addressing complex health challenges with AI-powered precision.

​

We are actively seeking strategic partners and investors to bring these life-changing therapies to patients worldwide.

 

Contact us for more information at invest@vaxxtx.com.